As of June 10, 2025, VisualMED Clinical Solutions Corp's estimated intrinsic value ranges from $0.01 to $0.06 per share, depending on the valuation methodology applied.
| Valuation Method | Fair Value (USD) | Implied Upside/Downside |
|---|---|---|
| Discounted Cash Flow (10Y) | $0.06 | +1605.6% |
| Discounted Cash Flow (5Y) | $0.03 | +704.6% |
| Dividend Discount Model (Multi-Stage) | $0.01 | +180.0% |
| Dividend Discount Model (Stable) | $0.02 | +354.2% |
| Earnings Power Value | $0.02 | +461.3% |
Is VisualMED Clinical Solutions Corp (VMCS) undervalued or overvalued?
With the current market price at $0.00, the stock appears to be significantly undervalued.
Intrinsic value represents the "true" worth of a company based on its fundamentals rather than market sentiment. We've employed multiple methodologies to triangulate VisualMED Clinical Solutions Corp's intrinsic value, including:
The cost of capital is a critical factor in valuation models, representing the required return for investors.
| WACC Component | Low | High |
|---|---|---|
| Long-term bond rate | 4.2% | 4.7% |
| Equity market risk premium | 5.0% | 6.0% |
| Adjusted beta | 0.67 | 1.1 |
| Cost of equity | 7.5% | 11.8% |
| Cost of debt | 5.0% | 5.0% |
| Tax rate | 26.2% | 27.0% |
| Debt/Equity ratio | 0.55 | 0.55 |
| After-tax WACC | 6.2% | 8.9% |
Our DCF model projects cash flows over 5-year and 10-year horizons, with the following key assumptions:
| DCF Model | Fair Value | Enterprise Value | % from Terminal Value |
|---|---|---|---|
| 5-Year Growth | $0 | $3M | 10.0% |
| 10-Year Growth | $0 | $6M | 42.1% |
| 5-Year EBITDA | $0 | $5M | 46.9% |
| 10-Year EBITDA | $0 | $6M | 37.2% |
The DDM values a company based on its expected future dividend payments. We used two approaches:
EPV assesses a company's value based on its current normalized earnings power, assuming no growth.
| EPV Component | Value |
|---|---|
| Normalized Earnings | $0M |
| Discount Rate (WACC) | 8.9% - 6.2% |
| Enterprise Value | $2M - $3M |
| Net Debt | $0M |
| Equity Value | $2M - $2M |
| Outstanding Shares | 99M |
| Fair Value | $0 - $0 |
| Selected Fair Value | $0.02 |
| Metric | Value |
|---|---|
| Market Capitalization | $0M |
| Enterprise Value | $0M |
| Trailing P/E | 2.18 |
| Forward P/E | 2.85 |
| Trailing EV/EBITDA | 11.10 |
| Current Dividend Yield | 0.00% |
| Dividend Growth Rate (5Y) | 0.00% |
| Debt-to-Equity Ratio | 0.55 |
To determine the most reliable intrinsic value estimate, we weigh each valuation method based on:
| Valuation Method | Weight | Weighted Value |
|---|---|---|
| Discounted Cash Flow (10Y) | 30% | $0.02 |
| Discounted Cash Flow (5Y) | 25% | $0.01 |
| Dividend Discount Model (Multi-Stage) | 20% | $0.00 |
| Dividend Discount Model (Stable) | 15% | $0.00 |
| Earnings Power Value | 10% | $0.00 |
| Weighted Average | 100% | $0.03 |
Based on our comprehensive valuation analysis, VisualMED Clinical Solutions Corp's weighted average intrinsic value is $0.03, which is approximately 793.1% above the current market price of $0.00.
Key investment considerations:
Given these factors, we believe VisualMED Clinical Solutions Corp is currently significantly undervalued with the potential for long-term appreciation based on the company's growth trajectory and financial strength.